ArticleHepatology (Baltimore, Md.)2025

Targeting mTORC2-dependent AKT/FOXO1/RNF125 signaling exploits a therapeutic vulnerability in c-MET-activated and β-catenin-mutated hepatocellular carcinoma.

Xue Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.